What is the price target for CHE stock?
8 analysts have analysed CHE and the average price target is 451.86 USD. This implies a price increase of 17.11% is expected in the next year compared to the current price of 385.84.
NYSE:CHE • US16359R1032
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CHEMED CORP (CHE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-27 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-02-27 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2026-01-22 | Jefferies | Downgrade | Buy -> Hold |
| 2025-11-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-09-10 | B of A Securities | Maintains | Buy -> Buy |
| 2025-09-02 | Jefferies | Upgrade | Hold -> Buy |
| 2025-07-31 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-25 | Jefferies | Initiate | Hold |
| 2025-06-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-30 | B of A Securities | Maintains | Buy -> Buy |
| 2025-04-28 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-05 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-05-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-03-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-02-29 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-01-17 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-10-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-07-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-07-27 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-05-01 | RBC Capital | Maintains | Outperform |
| 2023-04-28 | Oppenheimer | Maintains | Outperform |
| 2023-02-27 | RBC Capital | Maintains | Outperform |
| 2022-11-03 | RBC Capital | Maintains | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.264B 6.06% | 2.431B 7.37% | 2.53B 4.06% | 2.696B 6.56% | 2.864B 6.23% | 3.038B 6.08% | |
| EBITDA YoY % growth | 421.788M 4.35% | 470.279M 11.50% | 422.171M -10.23% | 496.51M 17.61% | 540.79M 8.92% | 583.22M 7.85% | |
| EBIT YoY % growth | 360.923M 4.62% | 407.23M 12.83% | 357.33M -12.25% | 424.23M 18.72% | 473.36M 11.58% | 518.21M 9.47% | |
| Operating Margin | 15.94% | 16.75% | 14.12% | 15.74% | 16.53% | 17.06% | |
| EPS YoY % growth | 21.45 8.55% | 23.14 7.88% | 21.59 -6.70% | 24.11 11.69% | 26.89 11.51% | 29.19 8.55% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 5.36 -4.88% | 5.46 27.85% | 6.04 14.61% | 7.27 13.23% | 6.30 17.68% | 6.28 15.08% | 6.46 7.02% | 7.65 5.18% |
| Revenue Q2Q % growth | 656.32M 1.45% | 666.26M 7.67% | 677.43M 8.41% | 696.29M 8.91% | 700.38M 6.71% | 709.82M 6.54% | 717.51M 5.92% | 743.23M 6.74% |
| EBITDA Q2Q % growth | 112.48M -0.11% | 114.16M 11.78% | 123.6M -4.74% | 146.27M -14.75% | 128.3M 14.06% | 127.77M 11.92% | 131.1M 6.07% | 152.38M 4.18% |
| EBIT Q2Q % growth | 92.042M -4.70% | 94.313M 35.01% | 104.74M 28.93% | 126.45M 18.46% | 113.58M 23.40% | 112.97M 19.78% | 116.22M 10.96% | 137.43M 8.68% |
All data in USD
8 analysts have analysed CHE and the average price target is 451.86 USD. This implies a price increase of 17.11% is expected in the next year compared to the current price of 385.84.
CHEMED CORP (CHE) will report earnings on 2026-04-23.
The consensus EPS estimate for the next earnings of CHEMED CORP (CHE) is 5.36 USD and the consensus revenue estimate is 656.32M USD.
The number of analysts covering CHEMED CORP (CHE) is 8.